142 related articles for article (PubMed ID: 29658435)
21. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
22. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
[TBL] [Abstract][Full Text] [Related]
23. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
24. [[Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo's group])].
Imaizumi M; Kondo T; Kamei H; Ichihashi H
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2397-403. PubMed ID: 2124433
[TBL] [Abstract][Full Text] [Related]
25. [Local immunotherapy of breast cancer: a case of advanced breast cancer improved by combined local injection therapy with OK-432 and rIL-2].
Fujimori M; Sugenoya A; Kobayashi S; Masuda H; Komatsu M; Takahashi S; Shimizu T; Tsuchiya S; Iida F
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2760-3. PubMed ID: 2551219
[TBL] [Abstract][Full Text] [Related]
26. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
[TBL] [Abstract][Full Text] [Related]
28. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion.
Nio Y; Nagami H; Tamura K; Tsubono M; Nio M; Sato M; Kawabata K; Hayashi H; Shiraishi T; Imai S; Tsuchitani T; Mizuta J; Nakagawa M; Fukumoto M
Br J Cancer; 1999 May; 80(5-6):775-85. PubMed ID: 10360655
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials.
Oba MS; Teramukai S; Ohashi Y; Ogawa K; Maehara Y; Sakamoto J
Gastric Cancer; 2016 Apr; 19(2):616-624. PubMed ID: 25804300
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
31. A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer.
Sato Y; Kondo M; Kohashi S; Takahashi N; Takahashi S; Sinohara T; Ono K; Matsuda M; Ryoma Y; Shiroto H; Kondo Y; Uchino J; Saito K; Todo S
J Immunother; 2004; 27(5):394-7. PubMed ID: 15314548
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group.
Cancer; 1987 Nov; 60(10):2394-402. PubMed ID: 2889522
[TBL] [Abstract][Full Text] [Related]
33. The role of systemic chemotherapy in the management of granulosa cell tumors.
Meisel JL; Hyman DM; Jotwani A; Zhou Q; Abu-Rustum NR; Iasonos A; Pike MC; Aghajanian C
Gynecol Oncol; 2015 Mar; 136(3):505-11. PubMed ID: 25546114
[TBL] [Abstract][Full Text] [Related]
34. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.
Kiselev VI; Ashrafyan LA; Muyzhnek EL; Gerfanova EV; Antonova IB; Aleshikova OI; Sarkar FH
BMC Cancer; 2018 Sep; 18(1):904. PubMed ID: 30236079
[TBL] [Abstract][Full Text] [Related]
35. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
Drews F; Bertelli G; Lutchman-Singh K
Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
[TBL] [Abstract][Full Text] [Related]
36. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
37. [Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations].
Shimizu Y; Tatsuki Y; Fujimoto I; Yamauchi K; Hasumi K; Masubuchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Dec; 44(12):1551-8. PubMed ID: 1484219
[TBL] [Abstract][Full Text] [Related]
38. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
39. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
[TBL] [Abstract][Full Text] [Related]
40. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Recchia F; Di Orio F; Candeloro G; Guerriero G; Piazze J; Rea S
Gynecol Oncol; 2010 Feb; 116(2):202-7. PubMed ID: 19880164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
